The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

@article{Vardiman2009The2R,
  title={The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.},
  author={James W. Vardiman and Juergen Thiele and Daniel A. Arber and Richard Brunning and Michael J. Borowitz and Anna Porwit and Nancy Lee Harris and Michelle M Le Beau and Eva Hellstr{\"o}m-Lindberg and Ayalew Tefferi and Clara Derber Bloomfield},
  journal={Blood},
  year={2009},
  volume={114 5},
  pages={
          937-51
        }
}
Recently the World Health Organization (WHO), in collaboration with the European Association for Haematopathology and the Society for Hematopathology, published a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues. The 4th edition of the WHO classification incorporates new information that has emerged from scientific and clinical studies in the interval since the publication of the 3rd edition in 2001, and includes new criteria for the… 
View on PubMed
t-aml.uchicago.edu
4,142 Citations
Highly Influential Citations
177
Background Citations
845
Methods Citations
455
Results Citations
16

4,142 Citations

Citation Type

Citation Type

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.
  • J. Vardiman
  • Biology, Medicine
    Chemico-biological interactions
  • 2010
TLDR
Although therapy-related MDS and AML (t-MDS/AML) often have genetic defects identical to those found in de noVO AML and de novo MDS, they are classified separately from deNovo AMLand MDS in order to emphasize their unique clinical and biologic properties.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
TLDR
The 2016 edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition.
World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants.
  • J. Vardiman, E. Hyjek
  • Biology, Medicine
    Hematology. American Society of Hematology. Education Program
  • 2011
TLDR
An understanding of the clinical, morphologic, and genetic features of the MPN variants will facilitate their diagnosis and, in most cases, correlation of clinical, genetic, and morphologic findings is required for diagnosis and classification.
World Health Organization Classification of tumors of hematopoietic and lymphoid tissues, 4th edition, 2008 – major changes from the 3rd edition, 2001*
The World Health Organization (WHO) classification of Tumors of Hematopoietic and Lymphoid Tissues (4th edition, 2008) represents an update of the 3rd edition, 2001.2 A summary of these changes in…
Health Organization ( WHO ) classification of tumors of the ematopoietic and lymphoid tissues : An overview with emphasis n the myeloid neoplasms ames
TLDR
The aim of the revision was to incorporate new scientific and clinical information that has accumulated since the previous edition in order to refine diagnostic criteria for previously described neoplasms and to introduce newly recognized disease entities.
The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know.
  • D. Arber
  • Medicine
    Seminars in hematology
  • 2019
TLDR
This review summarizes the WHO approach as well as the priority of specific features for disease classification of acute myeloid leukemia, including AML with myelodysplasia-related changes, and changes to specific categories.
WHO'S NEXT? THE WHO CLASSIFICATION OF MYELOID NEOPLASMS
rd edition) of the WHO classification of myeloid neoplasms included, for the first time in any widely used classification scheme, genetic information as diagnostic criteria not only for CML but also…
Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria
TLDR
The 2008 WHO diagnostic classification for myeloproliferative neoplasms has incorporated molecular markers with histologic, clinical and laboratory information into the diagnostic algorithms for the MPNs, and the classification of mast cell disease as an MPN is classified.
Diagnostic Approach in Acute Myeloid Leukemias in Line with WHO 2008 Classification
The last four decades have witnessed major transformations in the approach to the diagnostic work-up and therapeutics in the field of hematology. The identification of the Philadelphia chromosome in…
WHO Classification of Leukemia
TLDR
The World Health Organization (WHO) classification of leukemia and the closely related myelodysplastic syndromes (MDS) was the first classification system of hematological malignancies that used genetic information extensively to aid categorization.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 145 REFERENCES
The World Health Organization (WHO) classification of the myeloid neoplasms.
TLDR
The purpose of this communication is to outline briefly the WHO classification of malignant myeloid diseases, to draw attention to major differences between it and antecedent classification schemes, and to provide the rationale for those differences.
Tumors of the bone marrow
TLDR
The substantial focus on molecular genetic findings for each neoplasm parallels the ever-expanding role of genetics in disease classification and risk assessment and will provide readers with comprehensive information necessary for the clinical assessment of bone marrow neoplasms for years to come.
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
TLDR
An international review of lymphomas found that each of us had independently evolved ways of viewing these diseases that were essentially identical, and there was little divergence between European and US participants.
Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.
TLDR
Clinical, morphologic, and cytogenetic criteria for this 2008 WHO AML category, AML with myelodysplasia-related changes, support the clinical, pathologic, cytogenetics, and molecular features of 100 patients evaluated.
Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients.
TLDR
The present study validated the new classification of myelodysplastic syndromes with respect to prognostic importance, and correlate it with cytogenetic and hematological features in a large series of patients (n=1600) with a long-term follow up.
Definition of acute biphenotypic leukemia.
TLDR
BAL is an uncommon type of leukemia which probably arises from a multipotent progenitor cell and carries a poor prognosis, and it is likely that an intensive approach with high-dose therapy followed by bone marrow transplantation will be required to eradicate the disease permanently.
MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients.
TLDR
The data support a reassessment of the WHO classification for AML in the light of a more biologic understanding of AML and confirm that MLD is often associated with an unfavorable cytogenetic profile.
Myelodysplastic syndromes: an historical perspective.
TLDR
In 1900, Leube described a patient with severe megaloblastic anemia, preceding the development of overt leukemia, and not until recently have new validated risk factors been introduced, the most important being presence of a transfusion need.
A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases
TLDR
This work proposes minimal diagnostic criteria and a simple classification scheme which, while based on accepted morphological features and conforming with the recent suggestions of the WHO, allows for the special problems of myelodysplastic diseases in children.
Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival.
TLDR
Findings suggest that the detection of recurring cytogenetic abnormalities and multilineage dysplasia are the most significant features of current AML classification.
...
1
2
3
4
5
...